If there's one exclusion Catholic investors care about most, it's abortion. Every other category in the USCCB guidelines allows for revenue thresholds, prudential judgment, and engagement. Abortion gets a zero tolerance standard because Catholic moral teaching treats it as an intrinsic evil, not a matter of degree.

The Catechism of the Catholic Church paragraph 2270 is unambiguous: "Human life must be respected and protected absolutely from the moment of conception. From the first moment of his existence, a human being must be recognized as having the rights of a person, among which is the inviolable right of every innocent being to life."

Let's talk about how that teaching actually shows up in portfolio screening.

What counts as an abortion-connected company

The term "abortion-connected" is broader than most people realize. The USCCB Socially Responsible Investment Guidelines distinguish between several levels of involvement, and understanding the distinctions matters for building an actual portfolio.

Direct abortion providers. These are companies that physically perform abortions as part of their business. This category is small in the public markets because most abortion providers are nonprofit clinics or small private entities. Planned Parenthood isn't publicly traded. But some hospital systems do offer abortion services, and that creates complications for Catholic investors looking at healthcare REITs and hospital chains.

Abortion pill manufacturers. Danco Laboratories manufactures Mifeprex (mifepristone), the abortion pill. Danco is privately held, so retail investors aren't directly exposed. But GenBioPro produces a generic version, and the landscape keeps shifting as telehealth abortion services grow.

Contraceptives that can function as abortifacients. Plan B (levonorgestrel) and similar emergency contraceptives have abortifacient potential according to some interpretations of their mechanism of action. Bayer (BAYRY), Teva Pharmaceutical (TEVA), and Perrigo (PRGO) have exposure here.

Companies that donate meaningfully to abortion providers. This is where it gets controversial. Some Catholic investors argue that companies like Starbucks (SBUX), Amazon (AMZN), and various tech firms that provide abortion-related employee benefits should be excluded because their donations or benefits directly fund abortions. Others argue this is too remote to trigger exclusion.

Companies with fetal cell line connections in research. This crosses over with the embryonic stem cell research category. Pfizer (PFE), Moderna (MRNA), and Johnson & Johnson (JNJ) have varying levels of connection to fetal cell lines used in drug development. The moral analysis is different for each case.

The zero tolerance principle

Why does abortion get treated differently from, say, weapons manufacturing? The answer is in the moral theology of cooperation with evil.

Weapons are morally complex. The Catechism paragraph 2308 affirms that nations have the right to lawful defense, which means producing weapons isn't intrinsically evil. It depends on the type of weapon and the context. So revenue thresholds make sense: below 5 percent, the cooperation is remote; above it, you're materially supporting something potentially problematic.

Abortion is categorically different. The Church teaches in Evangelium Vitae (John Paul II, 1995) paragraph 62 that "direct abortion, that is, abortion willed as an end or as a means, always constitutes a grave moral disorder, since it is the deliberate killing of an innocent human being." There's no context that makes it permissible. There's no proportionate reason that justifies material cooperation.

That's why abortion gets zero tolerance in the USCCB guidelines. Any meaningful corporate involvement in abortion triggers exclusion, not because the USCCB is being unreasonable, but because the moral theology doesn't permit the usual cost-benefit analysis.

The pharmaceutical problem

Here's where it gets hard. Some of the largest pharmaceutical companies in the world have varying degrees of connection to abortion or abortifacient products. Excluding all of them means giving up significant portfolio diversification and accepting higher volatility.

Johnson & Johnson (JNJ) is a dividend aristocrat with a 60-plus year track record of raising dividends. It's also a contraceptive manufacturer. The Catechism paragraph 2370 condemns contraception as "intrinsically evil," so even setting aside the abortion question, JNJ fails the screening.

Pfizer (PFE) is the world's largest vaccine producer. Some of its vaccines used fetal cell lines from HEK-293 (derived from an abortion in the 1970s) in research stages. The USCCB Congregation for the Doctrine of the Faith has issued guidance that receiving such vaccines can be morally permissible under certain conditions, but owning stock in the producer is a different question.

Merck (MRK) has similar issues with certain products. Its Gardasil vaccine has been criticized on several fronts, though the core moral issue is more about contraception promotion than abortion.

Most Catholic mutual funds exclude all three. Ave Maria Mutual Funds (AVMNX) has publicly discussed its exclusion of these names. Knights of Columbus Asset Management maintains similar screens. Catholic Investor Small-Cap Fund also excludes them.

The result is that Catholic portfolios tend to underweight healthcare, which creates a different risk profile from broad market indexes.

The S&P 500 problem

If you own an S&P 500 index fund like SPY or VOO, you own pieces of every major company in America, including the ones that fail Catholic screens on abortion. Current estimates suggest that 15 to 25 percent of S&P 500 companies have some form of abortion-connected activity, whether through direct involvement, product lines, or corporate donations.

This creates a real problem for Catholic investors who want broad market exposure. You can't just buy SPY and call it done. You need to either use a screened Catholic fund, build a direct portfolio that excludes the problem companies, or use a strategy like Catholic Responsible Investments Equity Fund (CRIEX) that tries to track the index while excluding screened companies.

The cost of screening is real but manageable. Studies on Catholic screened portfolios generally show tracking error of 1 to 3 percent versus broad market indexes, sometimes higher depending on the screening rigor. Over long periods, that tracking error can compound meaningfully, though it sometimes works in the Catholic investor's favor and sometimes against.

Engagement versus divestment

One of the ongoing debates in Catholic investing is whether divestment or engagement is the better strategy. For most moral issues, the USCCB guidelines prefer engagement: own the stock, file shareholder resolutions, push for change.

For abortion, engagement is harder. You can't really engage Pfizer to stop being Pfizer. The company's business model includes products that conflict with Catholic teaching, and asking them to fundamentally change isn't realistic. So for the abortion category specifically, divestment is usually the practical answer.

That said, some Catholic investors do engage. The Interfaith Center on Corporate Responsibility has filed resolutions at various pharmaceutical companies on issues like drug pricing, access to essential medicines, and clinical trial ethics. These don't solve the underlying problem of contraceptive manufacturing, but they push companies toward better practices in adjacent areas.

Practical portfolio construction

How do you actually build a Catholic portfolio that excludes abortion-connected companies without giving up all diversification?

Start with healthcare. Instead of buying a broad healthcare ETF like XLV, look at specific companies with cleaner profiles. Thermo Fisher Scientific (TMO) makes lab equipment without the contraceptive or fetal cell line issues. Idexx Laboratories (IDXX) focuses on animal healthcare. Intuitive Surgical (ISRG) makes robotic surgery systems. These give you healthcare exposure without the moral conflicts of the big pharma names.

For biotech, companies like Regeneron (REGN) and Vertex Pharmaceuticals (VRTX) have cleaner profiles than the giants, though every biotech needs individual screening because research pipelines change.

For broad market exposure, Catholic Responsible Investments funds, Ave Maria funds, and Knights of Columbus funds are all options. Each has a slightly different screening methodology, so look at the specific approach each uses.

For individual stock selection, the FaithScreener tool and similar services give you screening capabilities so you can build a custom portfolio that reflects your exact standards.

The deeper question

There's a temptation to treat abortion screening as a box-checking exercise: exclude these tickers, you're done. But the USCCB guidelines push toward something deeper. Centesimus Annus paragraph 36 (John Paul II, 1991) talks about the decision to invest as a moral and cultural choice. That framing matters.

Screening out abortion-connected companies isn't just about avoiding moral contamination. It's about affirming that human life from conception is inviolable, and that you're not willing to profit from activities that deny that inviolability. It's a positive statement as much as a negative one.

When you do this consistently, something changes in how you think about ownership. The S&P 500 stops being an abstract basket and starts being a list of companies whose business practices you're implicitly endorsing. That's uncomfortable at first but ultimately clarifying. It makes your portfolio a more honest reflection of what you actually believe.

The Catechism paragraph 2319 puts it plainly: "Every human life, from the moment of conception until death, is sacred." Your portfolio can reflect that, or it can't. The choice is yours, but the USCCB guidelines make it clear which way the Church leans.

Abortion-Connected Companies and Catholic Portfolios: The Active Filter